
EMA delays Valneva vaccine approval
The CHMP’s action puts pressure on the French-Austrian vaccine developer, which wanted to market the vaccine from April on as the UK has already...

GSK acquires Sierra Oncology for 1.9bn
GSK is paying $1.9 bn in cash ($55 per share) for the deal. This is a 39 per cent premium to the Sierra share price on 12 April and a 63 per cent...

Abliva decides on a SEK200m financing to fund Phase 2/3 study
Swedish Abliva is focussing on mitochondrial medicine, developing therapeutics for primary mitochondrial diseases, orphan indications of high unmet...

Avantium closes financing for FDCA plant
Polyethylene furanoate (PEF) is 100% fossil-free when made from 2,5-furandicarboxylic acid (FDCA) with fructose as a carbon source und...

Unilever launches $120m venture with Genomatica
US biotechnology company Genomatica is a producer of sustainable materials derived from plant- or waste-based feedstocks instead of fossil fuels....

Ellipses Pharma licences SRB22 from SunRock Biopharma
Under the agreement, British Ellipses Pharma Ltd has been granted global rights to develop and commercialise SBR22 (which it renamed to EP0017) from...

CSL Behring files for MAA of haemophilia B gene therapy
Marburg-based CSL Behring has filed for accelerated EU marketing authorisation of Etranacogene dezaparvovec (EtranaDez), the first haemophilia B gene...